Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Expansion of Envisia Genomic Classifier Early Access Program
20 Medical Centers Across the U.S. Now Offering First Test to Improve Diagnosis of Idiopathic Pulmonary Fibrosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 5, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that 20 medical centers across the United States are now offering the Envisia
View HTML
Toggle Summary Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 , at 9:00 a.m.
View HTML
Toggle Summary Veracyte Announces Publication of Data Demonstrating “Real World” Performance of Afirma GSC in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of “real world” data showing that the Afirma® Genomic Sequencing Classifier (GSC) enables even more patients to avoid unnecessary surgery in thyroid cancer diagnosis compared
View HTML
Toggle Summary Veracyte Announces Third Quarter 2018 Financial Results
Revenue Grew 34 Percent and Genomic Test Volume Increased 23 Percent Company Increases Annual Revenue Guidance and Lowers Cash Burn Guidance for 2018 Conference Call and Webcast Today at 4:30 p.m. EDT SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 29, 2018-- Veracyte, Inc.
View HTML
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 15, 2018-- Veracyte, Inc. (Nasdaq: VCYT) will release its third quarter 2018 financial results after the close of market on Monday, October 29, 2018 . Company management will host a conference call and webcast to discuss financial results and
View HTML
Toggle Summary Veracyte Announces Presentation of “Real World” Clinical Utility Data at CHEST 2018 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
Preliminary data from ongoing, three-year registry study demonstrate that reduction in potentially harmful invasive procedures extends for first 12 months post-test SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that new interim data from a
View HTML
Toggle Summary Veracyte Announces Presentation of Data Confirming Envisia Genomic Classifier’s Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 8, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis
View HTML
Toggle Summary Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis
Study findings reported at the American Thyroid Association Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 6, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new findings from six studies reinforcing the “real world” performance of the next-generation Afirma Genomic
View HTML
Toggle Summary Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 27, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 , at 1:05 p.m.
View HTML
Toggle Summary Veracyte Announces New Data Reinforcing Clinical Value of Genomic Tests In Lung Disease Diagnoses to Be Presented at CHEST Annual Meeting 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 27, 2018-- Veracyte, Inc. (NASDAQ: VCYT) announced that new data highlighting the ability of the Percepta Bronchial Genomic Classifier to reduce unnecessary invasive procedures in lung cancer diagnosis will be shared in an oral presentation at
View HTML